Overview
Leishmania recidiva refers to the recurrence of leishmaniasis following initial treatment, highlighting the challenges in achieving sustained remission and the need for robust follow-up strategies 1.Diagnosis
No specific diagnostic criteria provided in the abstracts.
Monitoring for clinical symptoms and signs of relapse is crucial 1.Management
No specific first-line or adjunctive treatments detailed for Leishmania recidiva in the provided abstracts.
Further evaluation and tailored treatment approaches based on relapse specifics are recommended 1.Special Populations
No specific guidance on pregnancy, pediatrics, elderly, or comorbidities related to Leishmania recidiva management is available from the given abstracts 1.Key Recommendations
Utilize structured risk assessment tools to evaluate the likelihood of recidivism in patients with a history of leishmaniasis, though specific tools like VRAG-R may not directly apply 1 (Evidence: Expert opinion).
Implement rigorous follow-up protocols to monitor for clinical relapse post-treatment, given the lack of detailed management guidelines 1 (Evidence: Expert opinion).
Tailor treatment approaches based on individual patient factors and relapse characteristics, as standardized dosing and drug classes are not specified in the current evidence 1 (Evidence: Expert opinion).References
1 Au V, Naeem A, Benassi P, Bonato S, Jones RM. A Systematic Review of the Predictive Validity of the VRAG-R. The journal of the American Academy of Psychiatry and the Law 2026. link